Cyclooxygenase 2 is up-regulated and localized to macrophages in the intestine of Min mice by Hull, M A et al.
Data from multiple colon carcinogenesis studies in animals and
human epidemiological observations suggest that non-steroidal
anti-inflammatory drugs (NSAIDs) have chemopreventative
activity against colorectal cancer (Weiss and Forman, 1996;
Levy, 1997; Williams et al, 1997). A possible molecular target
of NSAIDs is believed to be cyclooxygenase 2 (COX-2 or
prostaglandin G/H synthase 2) (Levy, 1997; Williams et al, 1997).
The constitutive isoform of COX, COX-1, and the mitogen-
inducible isoform COX-2 both synthesize prostaglandin (PG)H2
(PGH2) from arachidonic acid, which, in turn, is converted to other
prostaglandin (PG) species depending on the profile of PG
synthases in a given cell (Levy, 1997). Exogenous PGE2 stimulates
proliferation of both human colon cancer cell lines and normal
mouse colonocytes (Qiao et al, 1995), and PGE2 levels are
increased in human carcinomas compared with normal colonic
mucosa (Rigas et al, 1993). Expression of COX-2 (but not COX-1)
is up-regulated in human colorectal adenomas and carcinomas
(Eberhart et al, 1994; Kargman et al, 1995; Sano et al, 1995;
Gustafson-Svard et al, 1996; Kutchera et al, 1996) and overexpres-
sion of COX-2 in rat intestinal epithelial cells is associated with a
malignant phenotype (Tsuji and DuBois, 1995). Furthermore, it
has recently been reported that administration of a specific COX-2
inhibitor prevents azoxymethane-induced colon carcinogenesis in
rats (Kawamori et al, 1998).
The effects of NSAIDs on colorectal adenoma formation and
growth in patients with familial adenomatous polyposis (FAP) and
corresponding murine models of this condition have been
particularly illuminating. Patients with FAP are heterozygous for a
germline  APC (adenomatous polyposis coli) mutation which
produces truncated APC protein (Nishisho et al, 1991). Loss of the
second APC allele leads to adenoma formation (Levy et al, 1994).
Sulindac (a NSAID and non-specific COX inhibitor) reduces
polyp formation in FAP patients (Williams et al, 1997). Two
murine polyposis models have been studied extensively. The
multiple intestinal neoplasia (Min) mutation is a heterozygous
nonsense mutation at codon 850 of the Apc gene (Moser et al,
1990; Su et al, 1992). After somatic mutation of the second Apc
allele, Min mice develop multiple polyps or adenomas in the small
intestine as well as a small number of colonic adenomas at around
2–3 months of age (Moser et al, 1990). Adenoma formation is
attenuated by sulindac (Boolbol et al, 1996; Chiu et al, 1997) and
other NSAIDs such as piroxicam (Jacoby et al, 1996). The ApcD716
knockout mouse has a truncating mutation at codon 716 of the Apc
gene and also develops adenomas in the small and large intestine
(Oshima et al, 1995). The important role of COX-2 in adenoma
formation in this model has been demonstrated by the highly
significant reduction in polyposis in ApcD716 mice which were
treated with a selective COX-2 inhibitor or had a deletion of one or
both copies of the Ptgs2 (murine COX-2) gene (Oshima et al,
1996).
Despite evidence that COX-2 overexpression is an important,
early event in murine adenoma formation and that NSAIDs have a
profound effect on adenoma formation, the cellular localization
of COX-2 protein in adenomas remains unresolved because
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Summary Expression of cyclooxygenase 2 (COX-2) is believed to play an important role in adenoma formation in murine polyposis models,
and inhibition of COX-2 activity may, at least, partly explain the chemopreventative activity of non-steroidal anti-inflammatory drugs against
colorectal cancer in humans. However, the mechanism by which COX-2 acts in intestinal tumorigenesis remains unresolved because of
conflicting data on the cellular localization of COX-2 in intestinal mucosa. Using immunohistochemistry with specific COX-2 antiserum, we
have shown that COX-2 protein is localized to interstitial cells at the base of and within adenomas of the small and large intestine of multiple
intestinal neoplasia (Min) mice. No COX-2 staining was observed in dysplastic epithelial cells within adenomas or in histologically normal
epithelium. Moreover, COX-2 staining was observed in lamina propria cells of histologically normal intestine of Min mice. No staining was
demonstrated in wild-type littermates. The rat monoclonal antibody F4/80 was used to show that COX-2-positive cells represented a subset
of the macrophage population present in the intestine of Min mice. Localization of COX-2 to macrophages implies a paracrine effect of COX-
2 function on epithelial cells in adenomas and also on histologically normal epithelium. Up-regulation of COX-2 expression in lamina propria
macrophages may precede loss of the second functional Apc allele in epithelial cells before adenoma formation in the Min mouse model of
intestinal tumorigenesis.
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Building, St James’s University Hospital, Leeds LS9 7TF, UKconflicting data have been obtained by several groups (Boolbol et
al, 1996; Oshima et al, 1996; Williams et al, 1996). Because the
cellular source of COX-2 in intestinal mucosa has profound impli-
cations for the mechanism by which COX-2 overexpression
promotes early tumorigenesis, we investigated COX-2 localization
in intestinal mucosa of Min mice by immunohistochemistry.
MATERIALS AND METHODS
Animals
C57BL/6J-ApcMin (Min) mice and wild-type littermates (+/+) were
obtained at 6–8 weeks of age from The Jackson Laboratory (Bar
Harbor, ME, USA). Male Min/+ animals were mated with +/+
females and the offspring genotyped using allele-specific poly-
merase chain reaction (PCR) (Dietrich et al, 1993). All animals
were reared under isolator conditions and were shown to be
pathogen free by bacteriological and serological testing. Animals
were fed with mouse standard diet (B&K Universal, Hull, UK)
and had free access to water. Animals were killed at specified
times using carbon dioxide inhalation. Immediately after death,
the gastrointestinal tract from duodenum to distal colon was
obtained and cut longitudinally to expose the entire mucosal
surface. Mucosa was washed thoroughly with phosphate-buffered
saline (PBS) and small intestinal and colonic tumours were
counted systematically by naked-eye examination. The smallest
countable tumours were 1 mm in diameter.
Immunohistochemistry
Specimens of intestine approximately 5–10 mm in length were
obtained from small intestine and colon of Min mice and wild-type
littermates immediately after death. Specimens were either fixed
in 4% paraformaldehyde overnight before embedding in paraffin
or were embedded in OCT compound (Merck, Poole, UK) and
frozen at – 70°C.
Paraformaldehyde-fixed sections (3 mm thick) were mounted on
glass slides coated with 3-aminopropyltriethoxysilane. Sections
were dewaxed in xylene (2 ´ 5 min) and rehydrated with 100%
ethanol followed by distilled water. Endogenous peroxidase
activity was blocked using 0.6% hydrogen peroxide in methanol
for 10 min. After washing with water, sections were placed in
10 mmol l–1 citrate buffer, pH 6.0, and heated to 80°C for 10 min 
in a microwave oven. Non-specific binding sites were blocked
with 5% swine serum (Dako, High Wycombe, UK) for 10 min at
room temperature.
Mouse COX-2 antiserum (Cayman Chemical, Ann Arbor, MI,
USA) was generated in rabbits by immunization with a synthetic
17-mer peptide (CY-SHSRLDDINPTVLIK) corresponding to a
unique C-terminal sequence in murine COX-2 (residues 584–598)
which is not present in COX-1 (Regier et al, 1993). This antiserum
was specific for COX-2 (rather than COX-1) when tested by
Western blot analysis (Otto and Smith, 1994).
Antiserum was diluted 1:100 in 5% swine serum and incubated
with sections for 60 min at room temperature. After washes with
water, sections were incubated with a 1:200 dilution of biotinylated
swine anti-rabbit immunoglobulin antibody (Dako) for 30 min at
room temperature, washed in tris-HCl, pH 7.8, and visualized using
streptavidin–biotin–horseradish peroxidase (Dako) and 3,3¢-
diaminobenzidene (0.7 mg ml–1)/hydrogen peroxide (0.05%).
Finally, sections were counterstained with Mayer’s haematoxylin,
dehydrated and mounted in diphenylxylene (Merck). Adjacent
sections were stained with haematoxylin and eosin (H & E).
Controls involved omission of the primary antiserum, incuba-
tion with an equivalent concentration of preimmune rabbit serum
(Dako) and preabsorption of antiserum with 10 mg ml–1 of its
cognate 17-mer peptide (Cayman Chemical) for 2 h at 4°C before
incubation with sections.
Frozen sections (8 mm thick) were fixed in 100% acetone for
60 s and air dried before immunohistochemistry, which was
carried out as described above.
Adjacent paraformaldehyde-fixed sections of Min mouse small
intestine were also stained with the rat monoclonal IgG2b antibody
F4/80 (a gift from Dr P Leenen, Erasmus University, Rotterdam,
The Netherlands) which recognizes mature murine macrophages
(Austyn and Gordon, 1981). The method used was as described
above except that there was no pretreatment of sections before
blocking non-specific binding sites and incubation of sections with
F4/80 was carried out overnight at 4°C. Biotinylated rabbit anti-rat
immunoglobulin antibody preabsorbed with mouse immuno-
globulin was obtained from Dako.
RESULTS
Min mice were killed on day 157 ± 23 (mean ± s.e.m.; n = 6) and
wild-type mice on day 221 ± 12 (n = 4). The number of adenomas
in Min/+ animals was similar to that previously described (Moser
et al, 1990; Boolbol et al, 1996). No adenomas were detected in
wild-type littermates.
Small intestinal and colonic adenomas from Min mice were
easily identifiable on H & E sections as raised lesions, 0.5–
2.0 mm in length, containing dysplastic epithelial cells above a
base of connective tissue and interstitial cells. The luminal surface
of adenomas was often eroded with some epithelial cell necrosis.
Neighbouring Min intestinal mucosa had normal morphology with
intact crypt and villus architecture and with no apparent increase
in lamina propria cell density compared with wild-type mucosa.
Immunohistochemistry for COX-2 revealed localization of
COX-2 protein in clusters of lamina propria cells at the base of
small intestinal adenomas (Figure 1A and B). Staining for COX-2
was also demonstrated in interstitial cells within adenomas
(Figure 1D), but there was no localization of COX-2 in dysplastic
epithelial cells within adenomas (Figure 1A and D). Interstitial
cells also stained for COX-2 in close proximity to areas of eroded
adenoma surface (Figure 1E). Although superficial epithelial cells
stained for COX-2 (Figure 1E), this was shown to be non-specific
(Figure 1F).
Examination of adjacent sections stained with H & E suggested
that the majority of COX-2-positive cells were macrophages
(speckled nuclear chromatin staining and irregular cell shape).
This was confirmed by immunohistochemistry with the mouse
macrophage marker F4/80 (Figure 1G and H).
A proportion of F4/80-positive cells in the lamina propria of
histologically normal small intestinal mucosa, at least 5 mm
distant from any adenoma, also stained for COX-2 (Figures 1J, L
and M), although, subjectively, the number of COX-2-positive
cells seemed lower than at the base of adenomas and many F4/80-
positive cells did not contain immunoreactive COX-2. By contrast,
lamina propria cells from small intestine of wild-type mice of a
similar age did not stain for immunoreactive COX-2 (Figure 1Q).
Less staining for COX-2 was evident in colonic mucosa of Min
mice than small intestine. In colonic adenomas, COX-2 staining
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Figure 1 COX-2 localization in Min (Min/+) and wild-type (+/+) mouse intestine. (A) Min/+ small intestinal adenoma. COX-2 was localized predominantly to
lamina propria cells at the base of the adenoma (arrows). Dysplastic epithelial cells did not stain for COX-2. Bar = 80 mm. (B) Min/+ small intestinal adenoma.
Localization of COX-2 in cells at the base of an adenoma (arrow). Bar = 40 mm. (C) Min/+ small intestinal adenoma. Staining of cells at the base of an adenoma
(arrow; compare with B) was abolished after preabsorption of COX-2 antiserum with its cognate peptide. Bar = 40 mm. (D) Min/+ small intestinal adenoma.
Localization of COX-2 in interstitial cells within an adenoma (arrow). Epithelial cells did not stain for COX-2. Bar = 40 mm. (E) Min/+ small intestinal adenoma.
Eroded epithelium at the luminal surface of an adenoma. COX-2 was localized to interstitial cells just below the erosion and within the body of the adenoma
(arrow). Bar = 40 mm. (F) Min/+ small intestinal adenoma. Abolition of staining of interstitial cells after preabsorption of COX-2 antiserum with COX-2 peptide
(compare with E). Staining of superficial epithelial cells was non-specific. Bar = 40 mm. (G) and (H) Min/+ small intestinal adenoma. F4/80-positive cells at the
base of an adenoma (arrow; G). These cells co-stained for COX-2 (arrow; H). Bar = 40 mm. (J) Min/+ normal small intestine. COX-2 was localized to lamina
propria cells within and at the base of villi (arrows). Bar = 80 mm. (K) Min/+ normal small intestine. Abolition of staining after preabsorption with COX-2 peptide
(arrows; see J). Bar = 80 mm. (L) Min/+ normal small intestine. COX-2 was localized to lamina propria cells within villi (arrows). Bar = 40 mm. (M) Min/+ normal
small intestine. F4/80 staining confirmed that COX-2-positive cells were macrophages. Bar = 40 mm. (N) Min/+ normal small intestine. Staining of frozen
sections confirmed the localization of COX-2 in lamina propria cells (arrows). Bar = 40 mm. (P) Min/+ normal small intestine. Abolition of specific COX-2 staining
of frozen sections after preabsorption with COX-2 peptide (arrows; see N). Bar = 40 mm. (Q) +/+ small intestine. No COX-2 staining of lamina propria cells was
seen (compare with J). Bar = 80 mm. (R) Min/+ colonic adenoma. Localization of COX-2 to interstitial cells within a colonic adenoma (arrows). Epithelial cells did
not stain for COX-2. Bar = 80 mm. (S) Min/+ normal colon. Very few lamina propria cells stained for COX-2 (arrow). The diffuse staining of superficial epithelial
cells was non-specific. Bar = 40 mmwas detected in a similar population of interstitial cells (Figure
1R), but COX-2-positive cells were fewer in number than in small
intestinal adenomas. Dysplastic epithelial cells of colonic
adenomas were clearly negative for COX-2 (Figure 1R). In
contrast to small intestine, histologically normal Min mouse
colonic mucosa contained only few COX-2-positive lamina
propria cells (Figure 1S). No COX-2 immunoreactivity was
detected in colonic mucosa from wild-type mice.
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Figure 1 (cont)The control sections confirmed the specificity of the observed
staining for COX-2. Preabsorption of COX-2 antiserum with the
COX-2 peptide abolished staining of interstitial cells in adenomas
(Figure 1C and F) and lamina propria cells in adjacent histologi-
cally normal small intestinal mucosa (Figure 1K). Additionally,
control sections incubated without primary antiserum or with
preimmune rabbit serum did not show any staining. We also exam-
ined frozen sections of Min mouse intestine to confirm our find-
ings on fixed tissue sections. Immunohistochemistry for COX-2
confirmed that there was no staining of adenomatous epithelium,
but there was staining of lamina propria cells (Figure 1N)
which was again prevented by preabsorption with COX-2 peptide
(Figure 1P).
DISCUSSION
We have demonstrated that COX-2 protein is localized to intersti-
tial cells (but not epithelial cells) in intestinal adenomas and also to
lamina propria cells in histologically normal intestinal mucosa of
Min mice of a similar age and phenotype to those previously
described (Moser et al, 1990, 1992; Dietrich et al, 1993; Boolbol et
al, 1996). In contrast, COX-2 immunostaining was not seen in
mucosa from wild-type littermates. Morphological analysis of H &
E sections suggested that the majority of COX-2-positive cells
were macrophages and this was confirmed by staining with F4/80
which recognizes all mature tissue macrophages in the mouse
(Austyn and Gordon, 1981). This finding is consistent with the
study of Kargman et al (1996) which demonstrated restriction of
COX-2 localization to a subset of macrophages in rat intestine.
The distribution of macrophages, which stained for F4/80, in small
intestine in this study is similar to that previously reported (Hume
et al, 1984; Soesatyo et al, 1990). Not all F4/80-positive cells 
co-localized COX-2 protein. As activation of cultured mouse
macrophages is associated with up-regulation of COX-2 expres-
sion (Lee et al, 1992), it is possible that COX-2 expression in small
intestine of Min mice is restricted to activated macrophages.
Further careful immunotyping and double labelling studies are
required to answer this question.
Our data on COX-2 localization in small intestinal adenomas
are in agreement with complimentary studies by Oshima et al
(1996), who reported that COX-2 was expressed in interstitial cells
within adenomas of ApcD716 mice using immunohistochemistry for
b-galactosidase to localize lacZ expression under the control of the
ptgs2 promoter. However, conflicting data have been provided by
Williams et al (1996), who described immunostaining for COX-2
in the adenomatous epithelium of a small number of polyps from
B6 ´ 129 Min/+ mice. These authors confirmed the specificity for
COX-2 (rather than COX-1) of their antibody, using cultured
intestinal epithelial cell lines, but did not provide controls
confirming the specificity of staining for COX-2 in fixed tissue
sections which had been predigested with trypsin.
Restriction of COX-2 localization to interstitial macrophages
implies the possibility of a direct and/or indirect paracrine effect of
COX-2-derived eicosanoid products on neighbouring epithelial
cells in adenomas. The nature of any putative macrophage–epithe-
lial cell signal is unknown, but eicosanoids such as PGE2 promote
proliferation of cultured human colorectal cancer cells (Qiao et al,
1995). It is also recognized that certain murine tumour-derived
macrophage cell lines synthesize large amounts of PGD2 (McGuire
et al, 1985), whose dehydration products, the PGJ2 series, could
alter gene expression by binding to the peroxisome proliferator-
activated receptor (PPAR) family of nuclear transcription factors
(Kliewer et al, 1995). Recently, PPARg expression has been shown
to be up-regulated in azoxymethane-induced colonic adenomas
and carcinomas in rats as well as a subset of human colon cancer
cell lines (DuBois et al, 1998).
We have also shown that lamina propria macrophages in small
intestinal mucosa of Min mice distant from any adenoma also
contain immunoreactive COX-2, unlike corresponding mucosa
from wild-type littermates. This finding is in agreement with data
provided by Boolbol et al (1996), who demonstrated increased
COX-2 expression (by Western blot analysis), increased
eicosanoid levels and decreased epithelial cell apoptosis in histo-
logically normal small intestine of Min mice at 110 days compared
with wild-type intestine. This study did not include immunohisto-
chemical detection of COX-2. However, Western blot analysis of
normal small intestinal mucosa of ApcD716 mice failed to detect
COX-2 (Oshima et al, 1996), and the one previous immunohisto-
chemical study of COX-2 in normal small intestine of B6 ´ 129
Min/+ mice failed to detect COX-2 (Williams et al, 1996).
Additional backcross experiments are required to investigate
whether intestinal COX-2 localization is related to the genetic
background of Min/+ mice. It is possible that the presence or
absence of COX-2 expression in certain mouse strains could
modify tumour phenotype in Min/+ mice, as has previously been
described for secretory type II phospholipase A2 (the gene product
of the Mom-1 locus) (Dietrich et al, 1993; MacPhee et al, 1995).
Although it has been suggested that induction of COX-2 expres-
sion in murine Apc +/– polyposis models occurs downstream of the
loss of the second Apc allele in epithelial cells (Prescott and White,
1996), our data demonstrate the presence of COX-2 in
macrophages in close proximity to epithelial cells which appear
morphologically normal and which, presumably, possess a full-
length Apc allele. Two previous studies have demonstrated that
histologically normal intestinal epithelium from Min mice contains
cells which have not undergone somatic mutation of their second
Apc gene (Levy et al, 1994; Luongo et al, 1994). Therefore, it is
unlikely that we have examined normal epithelium in the period
between loss of Apc heterozygosity and neoplastic transformation.
A recent study has demonstrated that histologically normal Min
mouse epithelium has decreased proliferation, apoptosis and
crypt–villus migration rates compared with wild-type mouse
epithelium (Mahmoud et al, 1997), which suggests a dominant-
negative effect of heterozygous Apc mutation on epithelial cells.
Up-regulation of COX-2 expression in neighbouring lamina
propria cells could also be a primary dominant-negative effect of
heterozygous Apc mutation in these cells or alternatively it could
be secondary to a stimulatory signal from Apc +/– epithelial cells.
There are also alterations in proliferative activity of histologically
normal colonic epithelium in FAP patients (Mills et al, 1995), and
so it would be interesting to assess whether COX-2 is localized to
lamina propria macrophages adjacent to histologically normal
epithelium in these patients.
An alternative explanation for the localization of COX-2 in
lamina propria cells next to histologically normal intestinal epithe-
lium is a ‘field effect’ of adenomas in Min mouse intestine.
Mahmoud et al (1997) ruled this out as a cause of changes in
epithelial cell kinetics by examining Min mouse intestine at 5
weeks of age (before adenoma formation). Our preliminary data
are consistent with this finding and confirm that COX-2 is
expressed by lamina propria macrophages in histologically normal
intestine of Min mice before adenoma formation (data not shown).
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et al, 1997) that colonic COX-2 expression is up-regulated as early
as 1 week after azoxymethane administration in rats (which is
several weeks before tumour formation in this model).
Localization of COX-2 in Min mouse colon has not been
reported previously. The distribution of COX-2 immunostaining
was similar to that in small intestinal adenomas and histologically
normal mucosa, although COX-2-positive cells were much less
frequent in colonic mucosa. This mirrors the distribution of
macrophages in normal mouse intestine (Hume et al, 1984) and
could explain the relative paucity of adenomas in the colon of Min
mice compared with small intestine (which contrasts with the FAP
phenotype).
There has been no published study of the immunohistochemical
localization of COX-2 in human adenomas. However, Eberhart et
al (1994) have reported that 9 out of 20 sporadic adenomas had
increased COX-2 mRNA expression by Northern blot analysis.
Another study failed to detect COX-2 protein by Western blot
analysis in any of four small FAP adenomas (Kargman et al,
1995). Therefore, it is possible that there is a similar localization
of COX-2 in human sporadic and FAP adenomas to that demon-
strated in this study.
In summary, we have shown that COX-2 is localized to lamina
propria macrophages in intestinal adenomas and histologically
normal intestinal mucosa of Min mice but not wild-type litter-
mates. The mechanism by which COX-2 expression is involved in
adenoma formation and growth is not known, but may involve
paracrine signalling by COX-2-derived eicosanoids from
macrophages to neighbouring epithelial cells. The elucidation of
the role of COX-2 in adenoma formation may lead to development
of alternative strategies for chemoprevention of colorectal cancer
which are not complicated by the morbidity and mortality which is
associated with NSAID use.
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